PolyPeptide

Samsung Biologics offers CHF1.46bn for PolyPeptide

20/07/26 -"Samsung Biologics announced a tender offer to acquire PolyPeptide Group for CHF 44.31/share, or CHF 1.46bn in market capitalisation, a premium of 6% to Friday’s closing price and 40% above ..."

PDF page sample
Pages
52
Language
English
Published on
20/07/26
Download
You may also be interested by these reports :
20/07/26
Bachem (ADD; Switzerland) is a peptide and oligonucleotide manufacturer, regarded as the most reliable partner in western economies as one of the few ...
20/07/26
Samsung Biologics announced a tender offer to acquire PolyPeptide Group for CHF 44.31/share, or CHF 1.46bn in market capitalisation, a premium of 6% ...
14/07/26
Pharmas’ AI investments pour broadly into two areas: Compute infrastructure, and AI models and platforms. Neither provides a long-term competitive ...
07/07/26
Following the June 2026 phase III R&D setback for an investigational drug, Riliprubart, targeting a rare neurological disease called CIDP (chronic ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO